ECSP21067104A - Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas - Google Patents

Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas

Info

Publication number
ECSP21067104A
ECSP21067104A ECSENADI202167104A ECDI202167104A ECSP21067104A EC SP21067104 A ECSP21067104 A EC SP21067104A EC SENADI202167104 A ECSENADI202167104 A EC SENADI202167104A EC DI202167104 A ECDI202167104 A EC DI202167104A EC SP21067104 A ECSP21067104 A EC SP21067104A
Authority
EC
Ecuador
Prior art keywords
amorphous
formulations
compound
fluoro
preparing
Prior art date
Application number
ECSENADI202167104A
Other languages
English (en)
Inventor
Mandar Dali
Akm Uddin
Onkar Vaze
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of ECSP21067104A publication Critical patent/ECSP21067104A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción en general se relaciona con formas amorfas de compuestos que tienen solubilidad acuosa mejorada y velocidades de disolución y dispersiones sólidas amorfas y formulaciones farmacéuticas orales de las mismas, y a procesos para preparar las mismas. La presente descripción se relaciona específicamente con formas amorfas de 5-fluoro-2-(6-fluoro-2-metil-1H-bencimidazol-1-il)-N-[4-(trifluorometil)fenil]pirimidin-4,6-diamina y dispersiones sólidas amorfas y formulaciones farmacéuticas orales de las mismas, y a procesos para preparar las mismas.
ECSENADI202167104A 2019-03-11 2021-09-09 Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas ECSP21067104A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962816402P 2019-03-11 2019-03-11

Publications (1)

Publication Number Publication Date
ECSP21067104A true ECSP21067104A (es) 2021-11-18

Family

ID=70166162

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202167104A ECSP21067104A (es) 2019-03-11 2021-09-09 Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas

Country Status (20)

Country Link
US (1) US20220185795A1 (es)
EP (1) EP3938368B1 (es)
JP (1) JP2022524424A (es)
KR (1) KR20210151061A (es)
CN (1) CN113853374B (es)
AU (1) AU2020235825A1 (es)
BR (1) BR112021017353A2 (es)
CA (1) CA3131801A1 (es)
CL (1) CL2021002365A1 (es)
CO (1) CO2021011836A2 (es)
EA (1) EA202192167A1 (es)
EC (1) ECSP21067104A (es)
HU (1) HUE062796T2 (es)
IL (1) IL286163A (es)
MX (1) MX2021010906A (es)
PE (1) PE20212270A1 (es)
PL (1) PL3938368T3 (es)
SG (1) SG11202109503TA (es)
WO (1) WO2020185648A1 (es)
ZA (1) ZA202106437B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2892045C (en) * 2012-11-21 2022-05-31 Ptc Therapeutics, Inc. Substituted reverse pyrimidine bmi-1 inhibitors
WO2020055544A2 (en) 2018-08-17 2020-03-19 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
MX2021010398A (es) * 2019-02-28 2022-01-18 Ptc Therapeutics Inc Metodo para tratar un mieloma multiple.
CA3134648A1 (en) * 2019-03-27 2020-10-01 Ptc Therapeutics, Inc. Combinations useful in a method for treating sarcoma
KR20220125232A (ko) * 2019-11-26 2022-09-14 이케나 온콜로지, 인코포레이티드 Ahr 억제제 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2892045C (en) * 2012-11-21 2022-05-31 Ptc Therapeutics, Inc. Substituted reverse pyrimidine bmi-1 inhibitors
EA028009B1 (ru) * 2013-01-22 2017-09-29 Ф.Хоффманн-Ля Рош Аг Фармацевтическая композиция с улучшенной биодоступностью
JP6878398B2 (ja) * 2015-04-03 2021-05-26 インパクト セラピューティクス インコーポレイティドＩｍｐａｃｔ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ Ｐａｒｐ阻害剤固形医薬剤型及びその使用
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide

Also Published As

Publication number Publication date
WO2020185648A1 (en) 2020-09-17
CO2021011836A2 (es) 2021-12-10
PE20212270A1 (es) 2021-11-30
EP3938368A1 (en) 2022-01-19
JP2022524424A (ja) 2022-05-02
US20220185795A1 (en) 2022-06-16
EA202192167A1 (ru) 2022-01-12
BR112021017353A2 (pt) 2021-11-16
PL3938368T3 (pl) 2023-12-27
CN113853374B (zh) 2025-02-28
MX2021010906A (es) 2021-10-01
ZA202106437B (en) 2025-01-29
EP3938368B1 (en) 2023-06-07
CA3131801A1 (en) 2020-09-17
AU2020235825A1 (en) 2021-09-30
IL286163A (en) 2021-10-31
CL2021002365A1 (es) 2022-04-22
CN113853374A (zh) 2021-12-28
HUE062796T2 (hu) 2023-12-28
KR20210151061A (ko) 2021-12-13
SG11202109503TA (en) 2021-09-29

Similar Documents

Publication Publication Date Title
CL2021002365A1 (es) Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas
MX392634B (es) Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta y un proceso para prepararlo
CY1124848T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν azd9291
EA201892007A1 (ru) 3-дезоксипроизводное и фармацевтические композиции на его основе
JO3430B1 (ar) مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
NZ631100A (en) Soft chewable pharmaceutical products
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201591531A1 (ru) Ингибиторы аргининметилтрансферазы и их применения
SA521421645B1 (ar) بيرولينات إندماجية تعمل كمثبطات بروتياز نوعي لأوبيكويتين 30
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
MX2017010945A (es) Preparacion solida.
EA201691538A1 (ru) Способ получения солей вортиоксетина
EA201692300A1 (ru) Производные карбоксамида
ECSP11011286A (es) Formulaciones orales sólidas de una pirido-pirimidinona
CY1125052T1 (el) Κρυσταλλικες μορφες
AR080127A1 (es) Inhibidores de la amida hidrolasa de acidos grasos, composiciones farmaceuticas y sus usos
MX2016001490A (es) Acido 2-[5-[n-(4-fluorofenil)carbamoíl]pirimidin-2-ilsulfanilmetil ]-4-(trifluorometoxi)fenil]borónico.
MX382199B (es) Formulacion farmaceutica.
MX381175B (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
MX377314B (es) Sal de un derivado de cefalosporina, forma sólida cristalina del mismo y método para su producción.
CL2017002180A1 (es) Formas cristalinas de un compuesto de pirrolopiridina
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
BR112018013356A2 (pt) sal de cloridrato, formas cristalinas de um sal de cloridrato e composição farmacêutica
CU20220008A7 (es) Forma polimórfica estable de 6-fluor0-9-metil-9h-b-carbolina
MX374540B (es) Desmopresina estabilizada.